Raydium (RAY) is struggling to maintain its bullish momentum above the $1.80 mark as a wave of futures selling and overextended technical conditions trigger a necessary market correction. Despite a strong 26% surge fueled by positive sentiment surrounding its partnership with Injective, the token is now retreating to seek downside liquidity. This cooling period is typical for assets that experience rapid vertical growth without significant consolidation, as traders look to lock in gains at psychological resistance levels.
The rally was fundamentally supported by Injective strengthening Raydium’s ecosystem visibility, which initially drew massive buy pressure to the Solana-based decentralized exchange (DEX). However, the surge pushed technical oscillators into overbought territory, prompting derivatives traders to reduce their exposure. Current market data suggests that the aggressive long positions taken during the peak are being squeezed, leading to a search for support at lower liquidity clusters.
For the broader DeFi sector in early 2026, this price action highlights the volatility inherent in ecosystem-driven pumps. While the Injective collaboration adds long-term utility to Raydium’s liquidity pools, the immediate market impact is being overshadowed by broader liquidity shifts within the Solana network. Regulatory clarity for DEX operations in the US continues to be a background factor, but the current movement is primarily driven by technical profit-taking and algorithmic rebalancing.
Investors should closely monitor the $1.55 to $1.65 price range, as this area holds significant historical liquidity that could act as a springboard for the next leg up. If Raydium can stabilize its funding rates and maintain spot volume above these levels, a retest of the $2.00 target remains plausible. However, a failure to hold the $1.50 support could signal a deeper retracement, potentially erasing the gains made during the recent Injective-led spike.